Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease
about
Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activitiesCrystallographic study of multi-drug resistant HIV-1 protease lopinavir complex: Mechanism of drug recognition and resistanceA potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitorActivities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitroIn vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolatesS-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1Construction of a human immunodeficiency virus type 1 (HIV-1) library containing random combinations of amino acid substitutions in the HIV-1 protease due to resistance by protease inhibitors.An Escherichia coli expression assay and screen for human immunodeficiency virus protease variants with decreased susceptibility to indinavirConserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virionsGenotypic testing for human immunodeficiency virus type 1 drug resistance.Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitorsEfficient identification of human immunodeficiency virus type 1 mutants resistant to a protease inhibitor by using a random mutant library.Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1.Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors.Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource SettingsEmergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detectionBoth P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitorCurrent and Novel Inhibitors of HIV ProteaseInterplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivityA Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.Comprehensive in vitro analysis of simian retrovirus type 4 susceptibility to antiretroviral agentsAnalysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavirHIV-1 drug resistance mutations: an updated framework for the second decade of HAARTThe Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failedCytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretroviralsAntiretroviral drug resistance in human immunodeficiency virus type 2.Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide.Human Immunodeficiency Virus Gag and protease: partners in resistance.Crucial stages of protein folding through a solvable model: predicting target sites for enzyme-inhibiting drugs.Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor.Protease inhibitors as antiviral agents.Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture.Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity.Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.
P2860
Q24550608-2C8DE55F-0E4E-4A8E-BF90-8F93DEB5FBC4Q27678735-7237222D-E9CF-4D17-8BEF-492F66F4E7AEQ28344457-13879063-BA24-4ABE-9EB8-860CB1828E2BQ28344594-EC49F6DB-EEC3-4C54-8852-766F9A915117Q28369030-9E9A2D33-F348-48B6-897A-7B5A638EDA28Q28378892-6D29145A-AF4A-4F7E-A3F5-F7179963A7FAQ28379173-EB1009A2-10FE-424C-9F22-7274BEA6A1FDQ28379223-2862818E-7211-4DB1-A270-EC285C869033Q28379544-D0ADFD9F-00A6-4F17-8525-E7E5578A6514Q30818137-427D1F72-5A85-40C3-BBF9-30635AFE870FQ31963272-EE4E735C-756C-4A30-A23C-C9D13CECA011Q33640739-850175CF-2E93-4BCA-8EB1-B1FCA8E2618CQ33906239-4CE72ACB-346C-4EA6-BB1C-85DCE7BA18FBQ33979580-0D029AF6-0A85-49A5-AB1F-F717BC7D6011Q34005107-7850FE29-9927-4616-AA0A-61A00AAE7D08Q34113737-322376D8-A506-4673-9676-CDB79101E608Q34454630-EE8253BD-F41A-4032-84D4-2CA9C25F2DE5Q34730950-74159874-077C-441B-8C1B-27968F9C3807Q35129066-34789A93-4627-4D69-9A6E-BBD081719F89Q35196297-6271DED0-F883-413D-A1BD-FDF2F5330CDFQ35259915-ABA0C824-4EDD-418E-B6F4-717DF2059EE9Q35689381-BE983AA5-93A7-44D7-B190-AA80C31AFF07Q35742512-AC3AE890-62C2-4927-BBD4-82B7200E055FQ35840811-5ABE9DB7-488C-42C8-A84E-E7A745E1410AQ36047851-41A1F1A8-7E55-4172-BA7B-024BC84BF7B6Q36760224-CA74209B-911B-4B3C-8AFB-C566D2DBCDF8Q36841895-BF23F865-1B03-435A-B595-3493929B868AQ36900010-A351EE69-73A1-42EB-A7A9-73BC767F2D89Q37018369-E1FEE017-D3DB-4954-AAFF-3E8354309288Q37021823-340544D3-755E-46E8-B943-40D18CF09A0BQ37247615-927F5A65-701E-4E91-B31D-B031B810CFDEQ37496287-5799219C-F535-4B2A-B4DA-91517F11ADC3Q37544670-282EA37A-A812-4771-B495-155160D37654Q38032330-969AE19F-BEDA-46EA-A805-D19F62CD4E4BQ38270232-1DCA501D-C7E8-41B5-B24C-E1665BBEE7C5Q39451655-CEC2600E-AACF-4086-ADA5-9FB52B1D718CQ39468942-529463AE-CD75-4941-86BC-12B087AADE9BQ39472141-E7D3CB80-CE31-43C1-898C-2C16582F8AC3Q39550164-76C15AFD-BF2E-45DC-A83D-8794CE1D63EBQ39550343-324B9E6D-DBB7-4E45-A253-74816F535139
P2860
Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease
description
1996 nî lūn-bûn
@nan
1996 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Antiviral and resistance studi ...... mmunodeficiency virus protease
@ast
Antiviral and resistance studi ...... mmunodeficiency virus protease
@en
Antiviral and resistance studi ...... mmunodeficiency virus protease
@nl
type
label
Antiviral and resistance studi ...... mmunodeficiency virus protease
@ast
Antiviral and resistance studi ...... mmunodeficiency virus protease
@en
Antiviral and resistance studi ...... mmunodeficiency virus protease
@nl
prefLabel
Antiviral and resistance studi ...... mmunodeficiency virus protease
@ast
Antiviral and resistance studi ...... mmunodeficiency virus protease
@en
Antiviral and resistance studi ...... mmunodeficiency virus protease
@nl
P2093
P2860
P1476
Antiviral and resistance studi ...... mmunodeficiency virus protease
@en
P2093
A K Patick
M Markowitz
P2860
P407
P577
1996-02-01T00:00:00Z